AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...

AbbVie (NYSE: ABBV) has announced a $3.5 billion non-cash impairment charge related to its potential schizophrenia treatment, emraclidine, following the drug's failure in Phase II trials last year.

BLAM! CRASH! When such a loud and disturbing noise occurs surrounding sleep, you might think you are dreaming even though you are awake. You might even think a gunshot or car crash has occurred ...

Capsida Biotherapeutics yesterday revealed US pharma major AbbVie (NYSE: ABBV) has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. As a result, ...

Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Recurrent Head ...

Fans joked that the actor should change his name to "Mark Baldberg" after he shared the clip Mark Wahlberg/Instagram Mark Wahlberg is “keeping it real.” On Thursday, Jan. 2, the 53-year-old ...

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

Dear coach Gautam Gambhir and the esteemed members of the BCCI, I write to you as a passionate follower of Indian cricket, deeply invested in the highs and lows of our team’s journey. In recent months ...

Few expected Arizona State to win the Big 12 in Kenny Dillingham's second season, and it likely wouldn't have been possible without Cam Skattebo. Skattebo, who played at the FCS level just two ...